VRTX insider sells 2,329 shares on three dates

Vertex Pharmaceuticals reported Form 144 activity showing insider dispositions.

Rhea-AI Filing Summary

Vertex Pharmaceuticals reported Form 144 activity showing insider dispositions. The filing lists three open-market sales by Carmen Bozic of 2,329 shares each on 02/27/2026, 03/13/2026 and 03/27/2026, with gross proceeds of $1,118,641.99, $1,122,088.91 and $1,050,262.55 respectively. The excerpt also shows earlier restricted stock vesting entries from 02/10/2025 (3,102 shares), 02/17/2025 (2,040 shares) and 02/24/2025 (1,846 shares) recorded as compensation.

Insights

Securities Compliance Analyst

Form 144 lists three equal share dispositions by an insider and prior restricted stock vesting events.

The filing records three reported sales by Carmen Bozic of 2,329 shares on specified March and February 2026 dates, each with the gross proceeds shown. These are reported dispositions under the securities rules.

Earlier entries show restricted stock vesting in 02/2025 totaling 6,988 shares across three vesting dates; those vestings appear as compensation acquisitions rather than registered sales. Timing, cash‑flow treatment, and whether sales were pre‑arranged are not stated in the excerpt.

Key Figures

Sale - 02/27/2026: 2,329 shares Sale - 03/13/2026: 2,329 shares Sale - 03/27/2026: 2,329 shares +3 more

6 metrics

Sale - 02/27/2026 2,329 shares sale by Carmen Bozic on <date>02/27/2026</date> for <money>$1,118,641.99</money>

Sale - 03/13/2026 2,329 shares sale by Carmen Bozic on <date>03/13/2026</date> for <money>$1,122,088.91</money>

Sale - 03/27/2026 2,329 shares sale by Carmen Bozic on <date>03/27/2026</date> for <money>$1,050,262.55</money>

Restricted stock vesting 02/10/2025 3,102 shares vesting recorded as compensation on <date>02/10/2025</date>

Restricted stock vesting 02/17/2025 2,040 shares vesting recorded as compensation on <date>02/17/2025</date>

Restricted stock vesting 02/24/2025 1,846 shares vesting recorded as compensation on <date>02/24/2025</date>

Key Terms

Form 144, Restricted Stock Vesting, Securities To Be Sold

3 terms

Form 144 regulatory

"Filing heading and sale records listing dates, share counts, and proceeds"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"Lines showing vesting dates and share quantities labeled as Compensation"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Securities To Be Sold regulatory

"Section listing securities with vesting type and issuer designation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Form 144 activity did VRTX disclose?

The filing discloses three sales of 2,329 shares each by Carmen Bozic on 02/27/2026, 03/13/2026, and 03/27/2026. The excerpt shows gross proceeds for each sale and separate restricted stock vesting entries from February 2025.

How much did Carmen Bozic receive from the reported VRTX sales?

The excerpt lists gross proceeds of $1,118,641.99, $1,122,088.91, and $1,050,262.55 for the three sales. These figures are shown alongside the corresponding sale dates in the filing excerpt.

Does the filing show any equity granted to insiders for VRTX?

Yes; the excerpt lists restricted stock vesting recorded as compensation: 3,102 shares on 02/10/2025, 2,040 shares on 02/17/2025, and 1,846 shares on 02/24/2025. These are shown as issuer compensation entries.

Are the sales reported in Form 144 indicated as part of a trading plan?

The provided excerpt does not state whether the sales were executed under a trading plan or were discretionary transactions. The filing text shown lists dates, share counts, and proceeds only.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 01:11 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001790029
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Bozic Carmen
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	6988	3144600.00	253805417	05/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/10/2025	Restricted Stock Vesting	Issuer			3102	02/10/2025	Compensation
Common	02/17/2025	Restricted Stock Vesting	Issuer			2040	02/17/2025	Compensation
Common	02/24/2025	Restricted Stock Vesting	Issuer			1846	02/24/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Carmen Bozic 50 Northern Avenue Boston MA 02210	Common	02/27/2026	2329	1118641.99
Carmen Bozic 50 Northern Avenue Boston MA 02210	Common	03/13/2026	2329	1122088.91
Carmen Bozic 50 Northern Avenue Boston MA 02210	Common	03/27/2026	2329	1050262.55

144: Remarks and Signature

Remarks
Date of Notice	05/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/20/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Carmen R. Bozic
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)